TransThera Sciences (Nanjing). Inc.
TransThera Sciences (Nanjing). Inc. (HKSE: 2617) is trading at HK$10.94, about ₹134 at today's HKD/INR rate, as of 30 Sep 2026, 4:08 AM ET, up 8.10% today. Indian residents can buy TransThera Sciences (Nanjing). from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
HK$10.08
Today's high
HK$11.06
52 week low
HK$9.01
52 week high
HK$246.00
2617 opened at HK$10.12, closed previously at HK$10.12, and has traded between HK$9.01 and HK$246.00 over the past 52 weeks.
About
TransThera Sciences (Nanjing), Inc., clinical stage biopharmaceutical company, discovers, develops, and commercializes small molecule therapies for oncology, inflammatory, and cardiometabolic diseases. The company provides Tinengotinib (TT-00420), a MTK inhibitor that is in clinical stage for the treatment of recurrent or refractory drug-resistant solid tumors. It also develops TT-00973, a kinase inhibitor for treating various cancers; TT-01488, a BTK inhibitor for the treatment of B-cell lymphoma; TT-01688, an oral S1P1 modulator for treating various inflammatory diseases; TT-00920, an oral PDE9 inhibitor used for treating central nervous system diseases; TT-01025, an oral irreversible VAP-1 inhibitor designed for the treatment of NASH; and TT-02332, a NLRP3 inhibitor for metabolic and inflammatory diseases. The company has a collaboration with Neurocrine Biosciences, Inc. to develop NLRP3 inhibitors for multiple disease. TransThera Sciences (Nanjing), Inc. was formerly known as Nanjing TransThera Biosciences Co. Ltd. and changed its name to TransThera Sciences (Nanjing), Inc. in July 2021. The company was incorporated in 2014 and is headquartered in Nanjing, China.
Key statistics
Avg. volume
9.98M
Market cap
HK$4.34B
P/E Ratio
-9.09
Price-to-sales ratio
106.27
Enterprise value
CN¥39.80B
Free cash flow yield
-0.63%
Debt-to-equity ratio
0.01
Return on equity
-71.08%
ROIC
-71.81%
Beta
3.25
Dividend yield
0.00%
Last dividend
HK$0.00
Financial overview
Revenue
CN¥0.00
Earnings per share
-CN¥0.76
Free cash flow
-CN¥253.68M
Net profit margin
-767.30%
Gross margin
87.74%
EBITDA
-CN¥290.82M
Revenue growth
0.00%
Similar securities
This is not an investment recommendation
How to buy TransThera Sciences (Nanjing). from India
Indian residents can buy TransThera Sciences (Nanjing). shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars and then to HKD.
Search for TransThera Sciences (Nanjing). and place an order
Find TransThera Sciences (Nanjing). by name or by its ticker, 2617, and choose an order type. Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share. TransThera Sciences (Nanjing). trades 7:00 am – 1:30 pm IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your TransThera Sciences (Nanjing). position in HKD and INR. TransThera Sciences (Nanjing). pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.
Read the full guide: how to invest in TransThera Sciences (Nanjing). from India
Trading and taxes when buying TransThera Sciences (Nanjing). from India
Trading and limits
- Trading hours
- 9:30 am – 4:00 pm HKT
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- NoneTransThera Sciences (Nanjing). does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
Custody. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
FAQs
Can Indian residents buy TransThera Sciences (Nanjing). stock?
Yes. TransThera Sciences (Nanjing). (2617) has been listed on the Hong Kong Stock Exchange since 2025, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars and then to HKD. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
How much does one TransThera Sciences (Nanjing). share cost in rupees?
One TransThera Sciences (Nanjing). share is HK$10.94 — about ₹134 at an HKD/INR rate of 12.24 on 29 Sep 2026. Both the TransThera Sciences (Nanjing). price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying TransThera Sciences (Nanjing). from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
What is the minimum I can buy of TransThera Sciences (Nanjing).?
Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share.
How are gains on TransThera Sciences (Nanjing). shares taxed in India?
Hong Kong generally does not levy capital gains tax on non-resident individual investors for HKEX-listed stocks, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the HKD/INR rate on the purchase and the sale date, so the rupee move counts alongside the TransThera Sciences (Nanjing). price. Paasa issues a capital-gains statement for your return.
Does TransThera Sciences (Nanjing). pay a dividend?
No. TransThera Sciences (Nanjing). does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.
When can I trade TransThera Sciences (Nanjing). from India?
The Hong Kong Stock Exchange trades 7:00 am – 1:30 pm IST in Indian time. It also halts for lunch, 9:30 am – 10:30 am IST. Orders can only execute during that window.
Is TransThera Sciences (Nanjing). a Hong Kong SAR China company, and does that change how it is taxed?
TransThera Sciences (Nanjing). trades on the Hong Kong Stock Exchange in HKD, but the company is domiciled in China. TransThera Sciences (Nanjing). trades as an ordinary share listed directly in Hong Kong, not a depositary receipt. Your India-side capital-gains treatment is the same either way.
Do I have to declare TransThera Sciences (Nanjing). shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your TransThera Sciences (Nanjing). holding, its cost and its closing value.
How do I sell TransThera Sciences (Nanjing). and bring the money back to India?
You sell during market hours (7:00 am – 1:30 pm IST) and the proceeds settle in HKD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.